Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Sofosbuvir and Ribavirin in DAA-Experienced HCV
NCT02356562Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2015
- Primary completion
- Oct 2016
- Modality
- Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 2, open-label, single-arm trial of ombitasvir, paritaprevir, ritonavir and dasabuvir in hepatitis C (HCV), sponsored by AbbVie Inc. Primary endpoint: Sustained Virologic Response 12 Weeks Posttreatment. Started Feb 2015; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02356562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356562.